ITA1029
ITA1029
ITA1029
from
$526.00
Price in reward points: 526
- Catalog: ITA1029
- Gene/Protein: CDC25C
- Product Description: Immunotag™ Phospho-CDC25C (Ser216) Antibody
Available Options
-
Description
Immunotag™ Phospho-CDC25C (Ser216) Antibody
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein Phospho-CDC25C (Ser216) Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC,IF/ICC,ELISA Recommended Dilution WB 1:500-1:2000 IHC 1:50-1:200, IF/ICC 1:100-1:500 Concentration 1 mg/ml Reactive Species Human Host Species Rabbit Immunogen A synthesized peptide derived from human CDC25C around the phosphorylation site of Serine 216 Specificity Phospho-CDC25C (Ser216) Antibody detects endogenous levels of CDC25C only when phosphorylated at Serine 216 Purification The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns. Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt Gene Name CDC25C Accession No. P30307 Alternate Names CDC 25; Cdc 25C; CDC25; CDC25C; Cell division cycle 25 homolog C; Cell division cycle 25C; Cell division cycle 25C protein; Dual specificity phosphatase Cdc25C; M phase inducer phosphatase 3; M-phase inducer phosphatase 3; Mitosis inducer CDC25; MPIP3; MPIP3_HUMAN; Phosphotyrosine phosphatase; PPP1R60; protein phosphatase 1, regulatory subunit 60; Description Functions as a dosage-dependent inducer in mitotic control. Tyrosine protein phosphatase required for progression of the cell cycle. When phosphorylated, highly effective in activating G2 cells into prophase. Directly dephosphorylates CDK1 and activates its kinase activity. Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 60kDa Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | Phospho-CDC25C (Ser216) |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC,IF/ICC,ELISA |
| Recommended Dilution | WB 1:500-1:2000 IHC 1:50-1:200, IF/ICC 1:100-1:500 |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human CDC25C around the phosphorylation site of Serine 216 |
| Specificity | Phospho-CDC25C (Ser216) Antibody detects endogenous levels of CDC25C only when phosphorylated at Serine 216 |
| Purification | The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | CDC25C |
| Accession No. | P30307 |
| Alternate Names | CDC 25; Cdc 25C; CDC25; CDC25C; Cell division cycle 25 homolog C; Cell division cycle 25C; Cell division cycle 25C protein; Dual specificity phosphatase Cdc25C; M phase inducer phosphatase 3; M-phase inducer phosphatase 3; Mitosis inducer CDC25; MPIP3; MPIP3_HUMAN; Phosphotyrosine phosphatase; PPP1R60; protein phosphatase 1, regulatory subunit 60; |
| Description | Functions as a dosage-dependent inducer in mitotic control. Tyrosine protein phosphatase required for progression of the cell cycle. When phosphorylated, highly effective in activating G2 cells into prophase. Directly dephosphorylates CDK1 and activates its kinase activity. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 60kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |